Recruiting
Early Phase 1

L-Carnitine

Sponsor:

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Code:

NCT07201714

Conditions

Heart Failure

Carnitine Deficiency

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Levocarnitine

Study Details

Brief summary:

Heart failure is a condition in which the heart is unable to pump blood effectively, leading to symptoms like being more tired, shortness of breath, and swelling in the body. Carnitine is a naturally occurring substance in the body that plays a role in turning fat into energy. This study will determine whether oral L-Carnitine supplementation can improve symptoms, enhance heart function and possibly improve the quality of life in individuals with heart failure.

Conditions

Heart Failure

Carnitine Deficiency

Study ID

NCT07201714

Start date

Nov 12, 2025

Status verified date

Apr, 2026

Completion date

Dec 31, 2026

Anticipated

Primary completion date

Dec 31, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Clinical-pathological diagnosis of heart failure with some degree of cardiorenal syndrome
  • Stage 1, 2, 3a, 3b, or 4 chronic kidney disease
  • Age ≥ 18 years
  • Able to speak and read English
  • Willing and able to provide consent

Exclusion Criteria:

  • Estimated GFR <15 mL/min/1.73m2 or Stage 5 chronic kidney disease
  • Currently undergoing renal replacement therapy of any kind
  • Pregnant, breastfeeding or intending pregnancy
  • History of seizures of any type
  • Known allergy to levocarnitine, magnesium stearate, microcrystalline cellulose or povidone
  • Unable to provide consent

Study Design

Enrollment

20 participants

Anticipated

Intervention Model

Single group

Primary purpose

Health Services Research

Interventions and Outcome Measures

Arms

experimental: Intervention

Oral Levocarnitine (L-Carnitine), 2970mg daily dose (990mg taken 3 times a day) for 3 months.

Interventions

Levocarnitine

Oral L-carnitine, 2970mg daily (950mg, to be taken 3 times a day) for 3 months.

Primary outcome measure

  • Recruitment Rate [ Time Frame: From study start to end of study at 52 weeks ]
  • Retention Rate [ Time Frame: From enrollment to end of treatment at 6 months ]
  • Intervention adherence [ Time Frame: From enrollment to end of study treatment at 6 months ]
  • Safety and Tolerability (adverse events) [ Time Frame: From enrollment to end of treatment at 6 months ]
  • Data Completeness [ Time Frame: From start of study to end of study at 52 weeks ]

Central Contacts and Locations

Central contacts

Kathy Koyle

519-685-8500kathleen.koyle@lhsc.on.ca

Amy Freeman, RN

519-685-8500amy.freeman@lhsc.on.ca

Locations

London Health Sciences Centre

Recruiting

London, Ontario, Canada, N6A 5W9

More Information

Sponsor

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Last update posted

Apr 20, 2026

Last verified

Apr, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's on 2026-04-20.